Opposition committed foeticide of govt's honest effort: PM Modi | Highlights

HDFC Bank CEO Sashidhar Jagdishan backs Keki Mistry to stay on as board chair

West Asia crisis: India ramps up fuel supply as 17.25 lakh LPG cylinders sold, auto LPG up 70%

Yogi Adityanath govt’s mega power plan: 34,000 MW supply as UP eyes record 33,375 MW demand

UP potato procurement cleared at Rs 6,500/ton; Centre boosts pulses support in Andhra & Karnataka

Good news for shipping sector: Cabinet clears Rs 12,980 crore maritime insurance pool amid Hormuz tensions

PM Narendra Modi to address the nation at 8:30 pm tonight, a day after women’s quota bill setback in Lok Sabha

Good news for central govt employees: 2% DA hike for January 2026 cleared; how much will salary increase?

Trump extends waiver permitting countries to buy Russian crude: Here's what it could mean for oil market

Strait of Hormuz will not remain open if US blockade continues, says Iranian Parliament Speaker

Kiran Mazumdar-Shaw was appointed to the Infosys board as an independent director in 2014, and as lead independent director in 2018.

Infosys announces Kiran Mazumdar-Shaw's retirement from board; Sundaram named lead independent director

These billionaire Indian women are trend-setters and are inspiring a young crop of female entrepreneurs to make their presence felt in the corporate world.

Women's Day Special: Billionaire Indian women making waves in corporate world

Biocon's&nbsp;Executive Chairperson Kiran Mazumdar Shaw talks about its Itolizumab,&nbsp;drug that has been approved by DGCI for restricted use on COVID-19 patients;&nbsp;response towards the drug;&nbsp;its&nbsp;current production capacity and plans to ramp-up the production among other things&nbsp;during an exclusive interview with Zee Business Executive Swati Khandelwal

Itolizumab is a breakthrough drug; Its Phase-IV trail will be conducted soon: Kiran Mazumdar Shaw, Biocon

The filing explained that in portfolio management services, the investor does not generally monitor the day-to-day investment decisions and in this case too, Mazumdar-Shaw had given no instruction to conduct the trade.

Infosys: Kiran Mazumdar-Shaw sold 1,600 shares without pre-clearance

Watch Zee Business Exclusive conversation with the director of Biocon Limited Kiran Mazumdar-Shaw on companies increase of market in bio similar products. 


Zee Business Exclusive conversation with Kiran Mazumdar-Shaw on 

Infosys also announced it has cleared pay hikes for its employees. The tech major&nbsp;said that it has rolled out salary hikes ranging from "mid-single digit to&nbsp; high-single digit " for a majority of its employees. The salary hike would be effective from April onwards

What kind of pay hikes did Infosys employees get in April? Attrition soars

Hurun Report on Tuesday released the sixth edition of its 'Hurun Global Rich List 2017' survey report, which showed that&nbsp;out of 2,257 billionaires in the world, only 15% or 152 were women.

Hurun Global Billionaire Rich list: Only 152 women billionaires out of 7 billion people

Biocon Q3 net up 65% to Rs 171 crore

Future jobs to be driven by digital tech: Kiran Mazumdar-Shaw

Time to act tough; no negative impact on economy: India Inc

Biocon Q1 consolidated net profit up 34% to Rs 1,666 million 